Litauen - litauisk - SMCA (Valstybinė vaistų kontrolės tarnyba)

chemoform ag, bahnhofstraße 68, 73240 wendlingen (vokietija). - trichlorizocianuro rūgštis, simklozenas; trichlorizocianuro rūgštis, simklozenas - veikliosios medžiagos cas nr.: 87-90-1, eb nr.: 201-782-8, veikliosios medžiagos pavadinimas: trichlorizocianuro rūgštis, simklozenas, koncentracija: 92% , veiklioji; veikliosios medžiagos cas nr.: 87-90-1, eb nr.: 201-782-8, veikliosios medžiagos pavadinimas: trichlorizocianuro rūgštis, simklozenas, koncentracija: 92% , veiklioji

Litauen - litauisk - SMCA (Valstybinė vaistų kontrolės tarnyba)

chemoform ag, bahnhofstraße 68, 73240 wendlingen (vokietija). - trichlorizocianuro rūgštis, simklozenas; trichlorizocianuro rūgštis, simklozenas - veikliosios medžiagos cas nr.: 87-90-1, eb nr.: 201-782-8, veikliosios medžiagos pavadinimas: trichlorizocianuro rūgštis, simklozenas, koncentracija: 92% , veiklioji; veikliosios medžiagos cas nr.: 87-90-1, eb nr.: 201-782-8, veikliosios medžiagos pavadinimas: trichlorizocianuro rūgštis, simklozenas, koncentracija: 92% , veiklioji

Den Europæiske Union - litauisk - EMA (European Medicines Agency)

teva gmbh - dimetilfumaratas - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresantai - dimethyl fumarate teva is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Den Europæiske Union - litauisk - EMA (European Medicines Agency)

accord healthcare s.l.u. - dimetilfumaratas - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresantai - dimethyl fumarate accord is indicated for the treatment of adult and paediatric patients aged 13 years and older with relapsing remitting multiple sclerosis (rrms).

Den Europæiske Union - litauisk - EMA (European Medicines Agency)

neuraxpharm pharmaceuticals s.l. - ublituximab - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresantai - briumvi is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (rms) with active disease defined by clinical or imaging features.

Den Europæiske Union - litauisk - EMA (European Medicines Agency)

sandoz gmbh - natalizumabas - multiple sclerosis, relapsing-remitting; multiple sclerosis - imunosupresantai - tyruko is indicated as single disease modifying therapy in adults with highly active relapsing remitting multiple sclerosis (rrms) for the following patient groups: patients with highly active disease despite a full and adequate course of treatment with at least one disease modifying therapy (dmt) (for exceptions and information about washout periods see sections 4. 4 ir 5. 1), or, patients with rapidly evolving severe rrms defined by 2 or more disabling relapses in one year, and with 1 or more gadolinium enhancing lesions on brain magnetic resonance imaging (mri) or a significant increase in t2 lesion load as compared to a previous recent mri.

Den Europæiske Union - litauisk - EMA (European Medicines Agency)

adienne s.r.l. s.u. - melphalan hydrochloride - multiple myeloma; hodgkin disease; lymphoma, non-hodgkin; precursor cell lymphoblastic leukemia-lymphoma; leukemia, myeloid, acute; neuroblastoma; ovarian neoplasms; hematopoietic stem cell transplantation - antinavikiniai vaistai - high-dose of phelinun used alone or in combination with other cytotoxic medicinal products and/or total body irradiation is indicated in the treatment of:multiple myeloma,malignant lymphoma (hodgkin, non-hodgkin lymphoma),acute lymphoblastic and myeloblastic leukemia,childhood neuroblastoma,ovarian cancer,mammary adenocarcinoma. phelinun in combination with other cytotoxic medicinal products is indicated as reduced intensity conditioning (ric) treatment prior to allogeneic haematopoietic stem cell transplantation (allo-hsct) in malignant haematological diseases in adults. phelinun in combination with other cytotoxic medicinal products is indicated as conditioning regimen prior to allogeneic haematopoietic stem cell transplantation in haematological diseases in the paediatric population as:myeloablative conditioning (mac) treatment in case of malignant haematological diseasesric treatment in case of non-malignant haematological diseases.

Den Europæiske Union - litauisk - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antinavikiniai vaistai - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Den Europæiske Union - litauisk - EMA (European Medicines Agency)

accord healthcare s.l.u. - plerixafor - multiple myeloma; hematopoietic stem cell transplantation - immunostimulants, - adult patientsplerixafor accord is indicated in combination with granulocyte-colony stimulating factor (g-csf) to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in adult patients with lymphoma or multiple myeloma whose cells mobilise poorly (see section 4. paediatric patients (1 to less than 18 years)plerixafor accord is indicated in combination with g-csf to enhance mobilisation of haematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in children with lymphoma or solid malignant tumours, either:- pre-emptively, when circulating stem cell count on the predicted day of collection after adequate mobilization with g-csf (with or without chemotherapy) is expected to be insufficient with regards to desired hematopoietic stem cells yield, or- who previously failed to collect sufficient haematopoietic stem cells (see section 4.

Den Europæiske Union - litauisk - EMA (European Medicines Agency)

baxalta innovations gmbh - vonicog alfa - von willebrando ligos - antihemoraginiai - veyvondi yra nurodyta suaugusiems (18 metų ir vyresnio amžiaus) su von willebrand liga (vwd), kai desmopressin (ddavp) gydymas vien yra neveiksmingos, arba ne nurodytas - gydymas kraujavimą ir chirurginio kraujavimo prevencijos chirurginio kraujavimo. veyvondi neturėtų būti naudojamas gydant hemofilija a.